tert-butyl 7-phenyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate | 1055880-52-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: tert-butyl 7-phenyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate
• 英文别名: tert-butyl 7-phenyl-3,5-dihydro-2H-1,4-benzoxazepine-4-carboxylate
• CAS: 1055880-52-8
• 化学式: C₂₀H₂₃NO₃
• 分子量: 325.408
• InChiKey: DFMZVJDQYIHBQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 7-phenyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 7-Phenyl-2,3,4,5-tetrahydro-1,4-benzoxazepine
  参考文献：
  名称：

  Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)

  摘要：

  A series of novel, highly potent, selective, and ATP-competitive mammalian target of rapamycin (mTOR) inhibitors based on a benzoxazepine scaffold have been identified. Lead optimization resulted in the discovery of inhibitors with low nanomolar activity and greater than 1000-fold selectivity over the closely related PI3K kinases. Compound 28 (XL388) inhibited cellular phosphorylation of mTOR complex 1 (p-p70S6K, pS6, and p-4E-BP1) and mTOR complex 2 (pAKT (S473)) substrates. Furthermore, this compound displayed good pharmacokinetics and oral exposure in multiple species with moderate bioavailability. Oral administration of compound 28 to athymic nude mice implanted with human tumor xenografts afforded significant and dose-dependent antitumor activity.

  DOI：

  10.1021/jm3007933
• 作为产物：
  描述：

  7-溴-2,3-二氢-1,4-苯并氧氮杂卓-4(5H)-羧酸叔丁酯 、 苯硼酸 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 12.0h， 以77.3%的产率得到tert-butyl 7-phenyl-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate
  参考文献：
  名称：

  BENZOXAZEPINE DERIVATIVES AND USE THEREOF

  摘要：

  公开号：

  EP2123644B1

文献信息

• Benzoxazepine derivatives and use thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08247403B2

  公开（公告）日：2012-08-21

  Compounds represented by the general formula (I): wherein each symbol is as defined in the description [with the proviso that 9-chloro-7-(1,1-dimethylethyl)-2,3,4,5-tetrahydro-1,4-benz-oxazepine and N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1,4-benz-oxazepin-7-yl)-5-oxazolidinyl]methyl]acetamide are excluded], salts of the same, and prodrugs thereof have selective activation effect on serotonin 5-HT2C receptor and are useful as preventive and therapeutic agents for lower urinary tract diseases, obesity, and/or pelvic organ prolapse.

  一般式（I）所代表的化合物：其中每个符号如描述中所定义[但9-氯-7-（1，1-二甲基乙基）-2,3,4,5-四氢-1,4-苯并噁唑环和N-[[(5S)-2-氧代-3-（2,3,4,5-四氢-1,4-苯并噁唑-7-基）-5-噁唑烷基]甲基]乙酰胺被排除]，其盐和前药在选择性激活5-羟色胺5-HT2C受体方面具有作用，并可用作预防和治疗下尿路疾病、肥胖症和/或盆腔器官脱垂的药物。
• US8247403B2
  申请人：——

  公开号：US8247403B2

  公开（公告）日：2012-08-21